US-based biopharmaceutical company Cognition Therapeutics has finished enrolling subjects in its Phase II SHIMMER study of CT1812 to treat mild-to-moderate dementia with Lewy bodies (DLB).
The study is evaluating the safety and effectiveness of CT1812, a new treatment for adults with DLB.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The double-blind, placebo-controlled trial has enrolled 120 adults with mild-to-moderate DLB, who will receive either a placebo or one of two doses of CT1812 orally for six months.
The study’s cognitive and executive function outcomes will be measured using the Montreal Cognitive Assessment and Cognitive Drug Research Battery tools.
The trial is being run in partnership with James Galvin, director of the University of Miami Miller School of Medicine’s Comprehensive Centre for Brain Health and the Lewy Body Dementia Association.
It is being supported by a $30m grant from the National Institute on Aging, a unit of the National Institutes of Health.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataCT1812 is also being studied in other clinical trials for Alzheimer’s disease and geographic atrophy secondary to dry age-related macular degeneration.
Cognition Therapeutics president and CEO Lisa Ricciardi said: “There are currently no approved disease-modifying therapies for DLB, leaving people living with this disease in desperate need of treatment options.
“The majority of patients with DLB have both Aβ and α-synuclein pathology. Because of our unique mechanism of action that targets both Aβ and α-synuclein oligomers, we believe that CT1812 may be able to slow the progression of disease.”
Cognition is preparing to report Phase II top-line results in the second half of this year after the last subjects have finished their six-month treatment regimen.
Last July, the company dosed the first participant in its Phase II MAGNIFY study of oral CT1812 to treat geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD).
